Zarek Pharmaceuticals Private Limited
About Zarek Pharmaceuticals Private Limited
Data last updated:
Zarek Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 20 April 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24304DL2019PTC348895. Its GSTIN is 10AABCZ3563D1ZR (Bihar).
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹1.5 Lakh. It is led by directors Kumar Pranay and Vitika Kumari Srivastav.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at C/O – Mrs Heventi Devi Plot No – D – 1/12 – A Kh No – 23/2 Mansa Ram Park Uttam Nagar, New Delhi, Delhi, India – 110059.
As per the financials filed for FY 2024, the company reported a revenue of ₹10.21 Lakh, a decline of 9% compared to the previous year. For the same year it recorded a net profit of ₹34,999 (net margin 3.4%) and EBITDA of ₹40,218 (EBITDA margin 3.9%). Revenue has grown at a compounded annual rate (CAGR) of 27% over three years.
Company details
Contact details
Zarek Pharmaceuticals Private Limited's registered office is in New Delhi, Delhi. Its e-mail address is in the company report.
- Email
- Registered AddressC/O – Mrs Heventi Devi Plot No – D – 1/12 – A Kh No – 23/2 Mansa Ram Park Uttam Nagar, New Delhi, Delhi, India – 110059
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Zarek Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Zarek Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Zarek Pharmaceuticals Private Limited, buy the company report.
Financials of Zarek Pharmaceuticals Private Limited
FY 2025 filings availableZarek Pharmaceuticals Private Limited reported revenue of ₹10.21 Lakh (down 9% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue fell 9% in the latest year, but over three years it has grown at a compounded annual rate (CAGR) of 27%. EBITDA rose 230% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹40,218 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹34,999 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 3.9% | ||||
| Net Profit Margin | 3.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Zarek Pharmaceuticals Private Limited, buy the company report.
Board of directors of Zarek Pharmaceuticals Private Limited
Zarek Pharmaceuticals has 2 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kumar Pranay | Director | 02 Sep 2020 | 6 Years 2 Months | Current |
| Vitika Kumari Srivastav | Director | 20 Apr 2019 | 7 Years 6 Months | Current |
Legal cases
No court or tribunal cases involving Zarek Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Zarek Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Zarek Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 10AABCZ3563D1ZR | Bihar | Active | 03 Oct 2019 |
To see the full GST registrations and return filing status of Zarek Pharmaceuticals Private Limited, buy the company report.
Recent activity
Zarek Pharmaceuticals Private Limited has 6 board changes on record since 2019: 4 appointments and 2 cessations. The latest: Neetu Sharma ceased to be Director on 11 Jun 2021.
Frequently asked questions
Zarek Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 20 April 2019 (7+ years old) and is registered under CIN U24304DL2019PTC348895.
Zarek Pharmaceuticals has 2 current directors:
- Kumar Pranay - Director
- Vitika Kumari Srivastav - Director
The latest financial statements of Zarek Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2020 are in the company report.
The GSTIN of Zarek Pharmaceuticals is 10AABCZ3563D1ZR, registered in Bihar.
The CIN (Corporate Identification Number) of Zarek Pharmaceuticals is U24304DL2019PTC348895. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Zarek Pharmaceuticals was incorporated on 20 April 2019, making it 7+ years old. It is registered with the Registrar of Companies, Delhi.
Neetu Sharma ceased to be Director on 11 Jun 2021. Kumar Pranay was appointed as Director on 02 Sep 2020. Sunny Kumar ceased to be Director on 31 Aug 2020. Zarek Pharmaceuticals has 6 board changes on record in total.
The registered office of Zarek Pharmaceuticals is at CO – Mrs Heventi Devi Plot No – D – 112 – A Kh No – 232 Mansa Ram Park Uttam Nagar, New Delhi, Delhi, India – 110059.
Zarek Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.
Zarek Pharmaceuticals can be reached at its registered office: CO – Mrs Heventi Devi Plot No – D – 112 – A Kh No – 232 Mansa Ram Park Uttam Nagar, New Delhi, Delhi, India – 110059.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
